Oof. What a day. My first thought, and something I

New Post Public Reply Private Reply Replies (1) Message Board
Respert24
894
Oof.

What a day.

My first thought, and something I fired off immediately to a fellow board member via email this morning, was “Wow, a press release at 9:26am where we hit a primary endpoint! But why no mention of 700mg? And why was their no mention of the BTD that Nader has thrown out multiple times as imminent once we get good results?”

Their response?

Samesies.

But here’s the thing. We all should know by now that we aren’t getting results quickly from these trials. There’s this unrealistic belief that once results are unblinded we should know within hours. While there’s some truth in the theory that they should be able to count deaths and do some quick math for a primary endpoint, there is far more that goes into compiling and presenting these results. It’s always slow and this PR was a good example. Nader said he believed we’d be hitting our primary and secondary endpoints of the 350mg arm a week and a half or so before Christmas. Then we were told we’d get results by Christmas. That second part didn’t happen, obviously. But think about how long it took and then consider we were just then getting the 700mg data for the first time soon after. It’s only been a couple weeks and we had two major holidays smushed in there. Be patient. There’s no reason to assume the results would be bad. By all accounts, the 700mg group should do equal to, or better than, the 350mg group.

I also was invested in 2019, which was a year where every time a good PR came about we’d be down the first day and then up the day or two after. There’s an old Emo Phillips joke about joke grenades, if I’m remembering who came up with the joke correctly. That’s how I always felt about the PR’s back in the year of our lord and savior, 2019. They always took extra time to land.

Some say this PR was a smokescreen for a bad BTD outcome. I highly doubt this is the case. We may not get the designation approved by the FDA, but since when does Nader get strategic with PR’s? Outside of trying to throw exciting “mights” and “maybes” in there, he’s definitely not playing three dimensional chess with his pressers. He’s dropped solid PR’s on the weekend, at 7pm eastern time, at 2am eastern time, and a variety of other inconsistent and not at all strategic times of the day.

Some wonder if the comment about biomarkers is because the 700mg results are bad and they’re hoping to glean some sort of positive information from the trial using those markers. To that I declare Shenanigans. You may as well call him ERecktnor for how excited he gets about biomarker data. He is heavily focused on biomarkers regardless of trial, so this isn’t some sort of feint to draw us away from some bad results. It’s him being him. They track this shit and it’s important. The more we know about exactly who this baby works on, and exactly why it’s working, the stronger our trials will be and the easier our approvals will be.

Please don’t short your brains, this isn’t all some constant game of strategery between Nader and the world. And Nader or the fair market are not the sole reasons we’ve had the run up to $10 and the fall back under a buck. Those are simple explanations for a much more complex answer. They’re both a part of things, but there’s so much more.

Some have said that with the volume we had today (around 7 million shares) this can’t be all shorts. But I’d ask you how then, did we see eight separate million share sell orders on the day we dropped hard from $10? Seven million shares at a buck or less would be easy if one were dead set on fuckery.

#Fuckery

Some people wonder if this or that is priced in. Hey guess what, we barely have a price right now at under a dollar. I think the only things priced in are the cost of the coffee mugs and extra microwaves because once you cook fish in a break room microwave a few times they’re never the same again. I pity the fool who thinks he can reheat some pasta after NP has blown up the ‘wave with yet another salmon cooked from raw.

Some say, “But Respert, you have your good looks and rapist’s wit to fall back on if this investment goes sideways. Not all of us are that fortunate.” And they wouldn’t be wrong. We all come at this investment opportunity with different circumstances and some of you are straight uggos. It’s science and statistics, don’t get mad at me. If anything, be mad at your parents. They had to know a mullet mixed with a lazy eye and that weird brillo pad looking hairstyle wasn’t going to produce the next Brad Pitt, but they bumped uglies anyways because this is America goddamnit. Everyone has something to offer, and if perfect facial symmetry isn’t your thing maybe you’re good at something else. I mean, I’d probably be good at it too, but I can lay back some to let you shine. I don’t need every spotlight. It’s not good for my perfect skin anyways.

#BlueSteel

Last but not least, let’s make some predictions.

I predict we get BTD and that it moves the needle. People track that shit and try to catch a wave. We’d also get some legit news coverage from it. It wouldn’t take that much buying pressure to overwhelm those exerting selling pressure.

We’ll get good results for 700mg. They just need the time they’ve always needed, and every other company has needed, to compile it all and get it ready for the stage. Hey youngblood, I’ve seen Q3 announcements of trials unblinding where the anticipated results are in Q2 of the following year. This shit can take time. Like steak you have to allow for both proper cook and proper rest time.

We’ll get a good partnership for Nash. Which will bring about a ton of new eyes. The media doesn’t seem to want to talk about Cytodyn but if a Merck or J&J type company enters into an agreement with ya boys they’ll happily spread that message far and wide for their old buddies in big pharma.

The longhauler trial will finally start in late January and fill by early February. I’ll be starting my own longhauler treatment center ala Bruce Patterson in the meanwhile. Strike while the iron is hot. It’ll be called “Rub Some Dirt On It Treatment Center” and I’ll deliver only old man medicine. Patients will either receive dirt to rub on their wounds, a story about how kids have it too easy these days, or Iodine. Man, I remember that Iodine used to be a common thing back when I was a kid. You couldn’t so much as stub a toe without getting the Iodine. Oh no, this just in, I’m now getting reports that Dr. Yo has read this post and is already promoting Iodine to treat Longhaulers for just $900 a week.

2022 will NOT be the year that I stop saying “unggggghhhh road humps” every time I roll over a road hump while my wife is in the car.

Last but not least, if you aren’t interested in swing trading and you believe that you’ve placed your money on the right horse, don’t sweat the swings down because your bet isn’t that on any given day the price will be X. Your bet is that after approvals and partnerships and saving lives the price will be XXX. None of that (minus those lives saved on RTT or CSP so far) has occurred yet so hold those tiny horses you tiny horse having weirdos. We’re just getting started.

Okay, that’s all I have for predictions. The booth is closed. You don’t have to go home but you can’t stay here. Life is like a box of chocolates. You don’t know what you’ve got til it’s gone. If it hadn’t been for Cotton-eyed Joe I’d been married long time ago. Did we just become best friends?

#TechnicalAnalysis

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

EFSI Shareholders on Alert Amid M&A Deal Scrutiny

Updated Category News Views 4

Eagle Financial Services Under the Microscope A buzz is picking up in the world of mergers and acquisitions, and this time, it's Eagle Financial Services, Inc. (NASDAQ: EFSI) caught in the crosshairs. What's the chatter all about? Well, it looks like Juan Monteverde and his crew over at Monteverde & Associates PC have set their sights on Eagle's proposed sale to John...

Continue Reading
Midlife ADHD in Women: New Challenges and Solutions

Updated Category News Views 4

ADHD Evolution in Women's Midlife They say change is the only constant, and boy, does that ring true for women navigating the turbulent seas of ADHD as they hit 40 and beyond. According to Germaine Swanson, the ADHD landscape changes dramatically in midlife, especially for women. We're talking about a mix of hormonal shifts, increasing life demands, and changes in brain...

Continue Reading
Agroz's Big Leap: New Supply Deal in Malaysia

Updated Category News Views 3

Agroz Inc. Executes a Game-Changing Deal If anyone thought the ag tech players were sitting idle, think again. Agroz Inc., noted for their innovative controlled-environment agriculture, just inked a pivotal deal with Harvest Hive in Malaysia. It's not just a nod to expansion—it's a strategic leap into the big leagues. Picture this: Harvest Hive's sprawling 500-acre farm...

Continue Reading
Global Communication Works Opens SignlLabs™ AI Licensing

Updated Category News Views 42

AI Signaling Moves Beyond GCW's Own Clients Remember when we first looked at GCW's SignlLabs and the idea of helping brands show up inside ChatGPT, Gemini, Claude, Copilot and Perplexity? Well, Global Communication Works is taking the next step. Instead of keeping its AI Signaling playbook inside the agency walls, GCW is now opening SignlLabs up for licensing

Continue Reading
Law Firm Gains Strength with Strategic New Hires

Updated Category News Views 1

Catching the latest twist in the legal scene, veteran criminal defense attorney John T. Floyd is stiffening the backbone of his Houston-based firm. Snagging both Christopher Choate and Mia Floyd, he's set to fortify his team representing folks caught in the snarl of Texas and federal criminal courts. New Faces, Massive Expertise Let's dig into Choate's credentials first....

Continue Reading
CUBEX Lights Up Veterinary Care with Mini Essential

Updated Category News Views 5

Inventory Woes? Meet Mini Essential If you’ve ever worked in or around veterinary hospitals, you know the old-school headaches of managing controlled substances. Picture this: piles of paper logs, end-of-shift recounting, and inevitable discrepancies that rear their ugly heads long after closing time. Enter CUBEX, shaking things up with their latest launch, Mini...

Continue Reading
ZEEKR's Shooting Brakes Dominate: Over 400K Sold

Updated Category News Views 3

ZEEKR's Stellar Performance in a Crowded Market Another month, another bumper crop for ZEEKR's shooting brakes. These beauties aren't just hanging in there; they're leading the pack. In August alone, global deliveries marched past the 10,000 mark for the third month running—a feat not easily achieved in today's saturated automotive landscape. It's no wonder the...

Continue Reading
Veho's Role in Redefining Beauty E-Commerce Delivery

Updated Category News Views 1

Veho Grabs Headlines with BeautyMatter Awards Nod Here's something a bit off the beaten path: Veho's been tapping into new wells of opportunity in the e-commerce sector, and their latest accolade demonstrates just that. Named a finalist in the 2026 BeautyMatter Awards under the Logistics category, they're making noise in all the right circles. Beyond Boxes: Transforming...

Continue Reading
Health Net's $2M Boost for Stanislaus Affordable Housing

Updated Category News Views 1

Joining the Fight Against California’s Housing Crisis Well, I'll be the first to say it's a breath of fresh air when a healthcare beast like Health Net starts investing in something as critical as affordable housing. This is no drop in the bucket—two million dollars is quite the commitment to fix some of the mess that’s been brewing in Stanislaus County, California....

Continue Reading
LeoLabs and SciTec Partner for $93.7M Space Force Deal

Updated Category News Views 2

LeoLabs and SciTec Join Forces for Space Dominance The space race ain't just about rockets blasting off anymore. It's about making sure we've got eyes everywhere, even on the back of our heads, so to speak. Enter LeoLabs teaming up with SciTec to help the U.S. Space Force upgrade their radar systems to something out of a sci-fi flick, armed with a $93.7 million contract...

Continue Reading

Top 5 Most Recently Viewed Articles

Virtune Expands Crypto Offerings with Two New ETPs in Germany

Updated Category News Views 164

Virtune's New ETP Launch in Germany Swedish regulated crypto asset manager Virtune is excited to announce the launch of its latest products: the Virtune Bitcoin Prime ETP and the Virtune Staked Solana ETP. These new offerings are now available for trading on Deutsche Börse Xetra, marking a significant expansion in the European crypto investment market. About Virtune and...

Continue Reading
Empowering Girls: State Farm Supports Career Readiness Initiative

Updated Category News Views 236

Empowering Young Women Through Education In a remarkable show of community support, Pace Center for Girls has received generous funding from State Farm Insurance to further their mission of empowering young women. With a grant totaling $60,000, they are enhancing their career and college preparation programs that benefit thousands of girls annually. Support for Education...

Continue Reading
AmazingContent Collaborates with LinkedIn for Enhanced Marketing

Updated Category News Views 214

AmazingContent Partners with LinkedIn to Elevate Executive Influence AmazingContent, a leader in AI-driven communication strategies, is excited to announce its membership in LinkedIn's Marketing Partner Program. This collaboration is a significant step toward helping marketing and communication teams enhance the voices of their executives on the world's largest...

Continue Reading
Seeking Justice: iLearningEngines, Inc. Class Action Details

Updated Category News Views 70

Class Action Overview for iLearningEngines, Inc. The Gross Law Firm has recently taken significant steps to notify shareholders of iLearningEngines, Inc. (NASDAQ: AILE) regarding a proposed class action lawsuit. This legal action addresses concerns impacting investors and emphasizes the need for shareholders to be vigilant and proactive in safeguarding their rights....

Continue Reading
Abbott Laboratories Issues Recall for FreeStyle Libre 3 Sensors

Updated Category News Views 186

Abbott Laboratories Issues Recall for FreeStyle Libre 3 Sensors Abbott Laboratories, a prominent player in the healthcare sector, has recently announced a recall for specific FreeStyle Libre 3 sensors. This action was taken after the company discovered that a small number of these sensors might deliver inaccurate high glucose readings. Health Risks Linked to the Recall...

Continue Reading